GleamWall
中文EN

VSTM Verastem, Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1526119 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY25.8%
TTM EPS YoY57.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin-193.7%
Net margin-178.4%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-88.0%
ROIC (approx.)—
Asset turnover0.49x

Leverage & solvency

Liabilities / assets95.6%
Debt / equity0.00x
Current ratio1.93x
Interest coverage-141.93x

Cash quality & payout

Operating cash flow / net income0.89x
Accruals ratio-9.5%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$24.01M$40.08M$18.67M$17.54M$11.24M$2.14M—$0
R&D expense$68.81M$41.34M$38.22M$31.67M$28.99M$24.79M$29.15M$20.81M
SG&A expense$26.48M$27.41M$22.30M$24.44M$21.01M$20.67M$15.02M$10.78M
Operating income-$75.22M-$32.71M-$44.90M-$41.48M-$40.72M-$43.76M-$44.17M-$31.59M
Interest expense$212,000$360,000$382,000$415,000$319,000$212,000$192,000$1.15M
Pretax income-$74.72M-$33.86M—-$32.92M-$98.52M-$25.93M——
Income tax$0$816,000$0—$0$0$0$185,000
Net income-$74.72M-$34.67M-$36.59M-$32.92M-$98.52M-$25.93M-$52.10M-$64.55M
EBITDA———-$41.46M-$40.71M-$43.76M-$44.16M-$31.58M
EPS (basic)-0.74-0.35-0.37—-1.35-0.39-0.96—
EPS (diluted)-0.74-0.35-0.46—-1.35-0.62-0.96—
Weighted avg. shares (diluted)101.24M100.12M99.15M—73.16M74.04M54.17M—
Balance sheet
Cash & equivalents$172.80M$136.35M$165.55M$204.99M$137.95M$164.56M$117.81M$89.06M
Short-term investments——$16.13M—————
Inventory$2.25M$2.40M$2.29M$1.83M$1.79M$1.17M——
Current assets$199.38M$176.16M$202.90M$223.41M$154.06M$174.27M$124.70M$94.96M
PP&E, net————$20,000$21,000$22,000$32,000
Intangibles$15.59M$15.87M$16.15M$16.43M$16.70M$15.64M——
Total assets$229.64M$206.51M$227.81M$246.44M$176.85M$196.26M$131.70M$101.54M
Current liabilities$103.33M$78.13M$66.84M$72.27M$59.71M$50.36M$35.62M$30.97M
Long-term debt———————$40.72M
Total debt———————$40.72M
Total liabilities$219.54M$156.53M$146.03M$189.25M$192.38M$160.21M$164.13M$130.43M
Shareholders' equity$10.10M$49.99M$81.78M$57.20M-$15.53M$36.06M-$32.43M-$28.89M
Net debt———————-$48.34M
Shares outstanding94.47M90.48M87.84M77.74M66.75M61.52M51.49M44.78M
Cash flow statement
Operating cash flow-$33.59M-$43.91M-$52.12M-$29.95M-$36.22M-$32.66M-$38.68M-$25.10M
Capital expenditure———————$0
Free cash flow———————-$25.10M
Investing cash flow-$7.50M$16.25M-$16.02M-$1.34M———$0
Financing cash flow$77.54M-$1.54M$28.69M$98.58M$17.88M$79.42M$67.43M$742,000
Depreciation & amortization———$18,000$2,000$0$10,000$7,000
Stock-based compensation$3.71M$3.43M$2.05M$2.02M$2.18M$3.41M$1.79M$2.02M

Free plan shows the latest 8 periods; Pro shows all 63 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.